OncoMatch/Clinical Trials/NCT03802695
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Is NCT03802695 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies OrcaGraft (Orca-Q) for acute myeloid leukemia.
Treatment: OrcaGraft (Orca-Q) — This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Prior alloHCT
Lab requirements
Kidney function
eGFR > 50 mL/min (MAC with tacrolimus) or > 30 mL/min (NMA/RIC or MAC without tacrolimus)
Liver function
Total bilirubin < 1.5x ULN (MAC) or < 3x ULN (NMA/RIC); ALT/AST < 3x ULN (MAC) or < 5x ULN (NMA/RIC)
Cardiac function
Ejection fraction ≥ 45% (MAC) or ≥ 40% (NMA/RIC)
eGFR > 50 mL/minute (MAC with tacrolimus) or > 30 mL/minute (NMA/RIC or MAC without tacrolimus) Cardiac ejection fraction ≥ 45 percent (MAC) or ≥ 40 percent (NMA/RIC) DLCO (adjusted for hemoglobin) ≥ 50 percent for MAC or ≥ 40 percent for NMA/RIC Liver function: Total bilirubin < 1.5x ULN (MAC) or < 3x ULN (NMA/RIC); ALT/AST < 3x ULN (MAC) or < 5x ULN (NMA/RIC)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UC Davis · Sacramento, California
- Stanford Health Care · Stanford, California
- Moffitt Cancer Center · Tampa, Florida
- Emory University · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03802695 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 78 years or younger and at least 12 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify